# Neoantigen-based Personalized DNA Vaccine With Retifanlimab PD-1 Blockade Therapy in Patients With Newly Diagnosed, Unmethylated Glioblastoma

> **NCT05743595** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Washington University School of Medicine** · enrollment: 27 (actual)

## Conditions studied

- Unmethylated Glioblastoma

## Interventions

- **BIOLOGICAL:** Personalized Neoantigen DNA vaccine
- **BIOLOGICAL:** Retifanlimab
- **DEVICE:** TDS-IM v 2.0 electroporation device

## Key facts

- **NCT ID:** NCT05743595
- **Lead sponsor:** Washington University School of Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-10-27
- **Primary completion:** 2026-04-07
- **Final completion:** 2029-03-09
- **Target enrollment:** 27 (ACTUAL)
- **Last updated:** 2026-05-04

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05743595

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05743595, "Neoantigen-based Personalized DNA Vaccine With Retifanlimab PD-1 Blockade Therapy in Patients With Newly Diagnosed, Unmethylated Glioblastoma". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT05743595. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*